genetic variation il28b predicts hepatitis c treatment-induced viral clearance 
chronic infection hepatitis c virus hcv affects million people worldwide leading cause cirrhosis north america1 although recommended treatment chronic infection involves -week course peginterferon-alpha-2b pegifn-alpha-2b or-alpha-2a pegifn-alpha-2a combined ribavirin rbv well known many patients will cured treatment patients european ancestry significantly higher probability cured patients african ancestry addition limited efficacy treatment often poorly tolerated side effects prevent patients completing therapy reasons identification determinants response treatment high priority report genetic polymorphism near il28b gene encoding interferon-lambda- ifn-lambda- associated approximately twofold change response treatment among patients european ancestry p x - african-americans p x - genotype leading better response substantially greater frequency european african populations genetic polymorphism also explains approximately half difference response rates african-americans patients european ancestry 
